Astal Laboratories schedules board meeting to approve FY26 results

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Astal Laboratories schedules board meeting for September 4, 2026
  • Agenda includes approval of financial results for FY ended March 31, 2026
  • Board to approve notice and logistics for 33rd Annual General Meeting
  • Appointment of scrutinizer for AGM voting is also on the agenda
powered bylight_fuzz_icon
49727434

*this image is generated using AI for illustrative purposes only.

Astal Laboratories Limited has scheduled a board meeting for September 4, 2026, to consider and approve the financial results for the fiscal year ended March 31, 2026.

The company informed the Bombay Stock Exchange on August 31, 2026, that the meeting will also address the notice for its 33rd Annual General Meeting. The board intends to fix the day, date, time, and venue for the upcoming AGM during this session.

Agenda Details

The board meeting agenda includes several key corporate governance items alongside the financial approvals. The directors will approve the Board Report along with all necessary annexures for FY26.

Additionally, the board plans to appoint a scrutinizer to oversee voting procedures during the AGM, including remote e-voting processes. The meeting will be held at the company’s corporate office in Gachibowli, Telangana.

Agenda Item Description
Financial Results Approval of results for FY ended March 31, 2026
AGM Notice Approval of notice for 33rd AGM
AGM Logistics Fixing date, time, and venue for AGM
Scrutinizer Appointment of scrutinizer for voting

The disclosure was made in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+2.08%-1.62%+4.11%+4.93%-6.81%0.0%

How are analysts expecting Astal Laboratories' FY26 financial performance to compare with previous fiscal years given current market conditions?

Will the board propose any changes to dividend policy or capital allocation strategies during the upcoming AGM?

Are there any anticipated strategic shifts or new business verticals that might be highlighted in the Board Report for FY26?

Astal Laboratories Q1 Results: Unaudited financials filed for June 2026

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

Astal Laboratories Limited filed its unaudited Q1FY26 standalone and consolidated financial results with BSE. The company confirmed publication in major newspapers on August 15, 2026, adhering to SEBI LODR Regulation 47. No specific financial figures were disclosed in this procedural filing.

powered bylight_fuzz_icon
48422872

*this image is generated using AI for illustrative purposes only.

Astal Laboratories Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the Bombay Stock Exchange. The filing serves as a formal notification of the company’s compliance with disclosure norms under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company informed the exchange that the extract of the financial results was published in the August 15, 2026 editions of The Financial Express and The Business Standard (English) and The Jansatta (Hindi). This publication fulfills the requirement under Regulation 47 of the SEBI LODR Regulations.

Regulatory Compliance

The submission was made pursuant to Regulation 30 of the SEBI LODR Regulations, which mandates timely disclosure of financial performance to listed entities. Astal Laboratories provided copies of the relevant newspaper publications to the exchange for record-keeping purposes.

Mahendra Kumar, Company Secretary and Compliance Officer at Astal Laboratories, signed the submission on August 16, 2026. The company previously operated under the name Macro International Limited.

What the Numbers Show

The current filing is a procedural notice confirming the publication of financial results. It does not contain specific financial metrics such as revenue, profit, or cash flow figures. Investors must refer to the full detailed format filed with the stock exchange or the published newspaper extracts for granular financial data.

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+2.08%-1.62%+4.11%+4.93%-6.81%0.0%

How will the upcoming release of audited annual results impact Astal Laboratories' stock valuation compared to these unaudited quarterly figures?

What strategic initiatives is Astal Laboratories prioritizing to drive revenue growth in the pharmaceutical sector following its rebranding from Macro International?

How might changes in SEBI's LODR regulations affect the compliance costs and reporting timelines for mid-cap listed entities like Astal Laboratories?

More News on Astal Laboratories

1 Year Returns:-6.81%